Halozyme Therapeutics, Inc. $HALO Shares Purchased by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,933 shares of the biopharmaceutical company’s stock after purchasing an additional 10,910 shares during the period. Halozyme Therapeutics comprises 3.9% of Cooper Investors PTY Ltd.’s investment portfolio, making the stock its 7th largest holding. Cooper Investors PTY Ltd. owned approximately 0.06% of Halozyme Therapeutics worth $7,279,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NorthCrest Asset Manangement LLC increased its position in Halozyme Therapeutics by 27.7% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company’s stock valued at $6,333,000 after acquiring an additional 12,511 shares during the period. GK Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $178,000. Balefire LLC lifted its holdings in shares of Halozyme Therapeutics by 9.9% during the third quarter. Balefire LLC now owns 3,227 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 291 shares during the period. Wedmont Private Capital bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $294,000. Finally, Journey Retirement Planning & Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $332,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HALO. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. TD Cowen upped their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.50.

Halozyme Therapeutics Trading Down 1.3%

Shares of NASDAQ HALO traded down $1.46 during midday trading on Tuesday, reaching $109.62. The stock had a trading volume of 1,772,697 shares, compared to its average volume of 1,931,753. The firm has a market cap of $12.44 billion, a price-to-earnings ratio of 32.72, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $116.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company’s 50 day moving average price is $106.78 and its 200 day moving average price is $83.54.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 EPS. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 18,996 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 over the last quarter. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.